$83.4 Million is the total value of Canaan Partners X LLC's 3 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NXTC | Buy | NextCure Inc | $86,980,000 | +15.7% | 4,056,884 | +100.0% | 52.17% | -37.0% |
| IDYA | Buy | IDEAYA Biosciences Inc | $75,618,000 | +589.8% | 5,321,426 | +100.0% | 45.36% | +275.9% |
| ITRM | Buy | Iterum Therapeutics plc | $4,124,000 | -12.2% | 3,466,340 | +100.0% | 2.47% | -52.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IDEAYA Biosciences Inc | 16 | Q3 2023 | 96.1% |
| Iterum Therapeutics plc | 12 | Q3 2022 | 6.0% |
| NextCure Inc | 8 | Q3 2021 | 82.8% |
| Berkshire Grey Inc | 8 | Q2 2023 | 41.8% |
| Astra Space Inc | 4 | Q2 2022 | 51.2% |
| MONEYLION INC | 2 | Q3 2023 | 3.9% |
View Canaan Partners X LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-10-11 |
| 13F-HR | 2023-07-13 |
| 13F-HR | 2023-04-06 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-10-31 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-04-28 |
| 13F-HR | 2022-02-03 |
| 4 | 2022-01-04 |
| 13F-HR | 2021-11-15 |
View Canaan Partners X LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.